Deep Bio News Today

Deep Bio today announced the publication of a study evaluating the performance of its AI algorithm for breast cancer analysis to accurately differentiate between invasive ductal carcinoma (IDC) lesions from non-invasive ductal carcinoma in situ (DCIS) lesions in biopsies taken after breast cancer surgery.

/C O R R E C T I O N -- Deep Bio/

/PRNewswire/ -- DeepBio announced today that it has been awarded the CES Innovation Award as the first Korean cancer diagnosis A.I. company in CES 2024, the...

/PRNewswire/ -- Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation in the...

"In April 2023, Indica Labs Inc. (US) signed an agreement with Lunit Inc. (South Korea). The agreement helped to provide a fully interoperable solution between Indica Labs' HALO AP image management software platform and

During the forecast period. The AI in pathology market refers to the sector within the healthcare industry that encompasses the development, deployment,...

/PRNewswire/ -- In the near future, the AI in pathology industry is poised to revolutionize the field of diagnostics and patient care. Advancements in machine...

Seoul, South Korea (PRWEB) May 11, 2023 -- Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that Dr.

SEOUL, South Korea (PRWEB) March 10, 2023 -- Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software will share three

SEOUL, South Korea (PRWEB) November 15, 2022 -- Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered